You are here

Real-time qPCR assay for detection of ALT associated telomeric C-circle DNA in bl

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA168124-01A1
Agency Tracking Number: R43CA168124
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
9700 GREAT SENECA HWY SUITE 313
ROCKVILLE, MD 20850-3307
United States
DUNS: 54571370
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANDREI MALYKH
 (301) 527-0804
 andrei@cbibio.com
Business Contact
 ANDREI MALYKH
Phone: (240) 207-2314
Email: andrei@cbibio.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): The overall goal of the proposed project is to investigate the feasibility of employing real-time qPCR method for detection of telomeric C-circle DNA in peripheral blood of patients with cancers that utilize Alternative Lengthening of Telomeres (ALT) as their Telomere length Maintenance Mechanism (TMM). Telomeric C-Circle DNA has been demonstrated to be specific for ALT, thus enabling the first quantitative test for ALT activity. In 85% of cancers, cells maintain telomere length due to increased activity of telomerase, while 5 - 15% of tumors from most cancer types rely on the ALT mechanism for continued growth and survival. It is therefore imperative to determine the prevalence of ALT[+] tumors. Initial retrospective analyses showed that ALT ranges from 25% to 60% in sarcomas and 5% to 15% in carcinomas. ALT can be also a potential 'escape route' for tumor cells to survive under pressure from treatment with anti-telomerase drugs. Recently published results of in vit

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government